Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Nat Commun. 2020 Aug 26;11(1):4253. doi: 10.1038/s41467-020-17907-w.

Abstract

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus* / drug effects
  • Betacoronavirus* / pathogenicity
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Cricetinae
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • Mice
  • Models, Biological*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Primates
  • SARS-CoV-2
  • Treatment Failure

Substances

  • Antiviral Agents
  • Hydroxychloroquine

Supplementary concepts

  • COVID-19 drug treatment